# US 2010/0136660 A1 · Methods for producing members of specific binding pairs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136660 A1
- Document ID: US20100136660A1
- Status: Published application
- Kind: A1
- Application number: 12/648,269
- Filed: 2009-12-28
- Published: 2010-06-03
- Earliest claimed: 1990-07-10
- Inventors: John McCafferty; Anthony Richard Pope; Kevin Stuart Johnson; Henricus Renerus Jacobus Mattheus Hoogenboom; Andrew David Griffiths; Ronald Henry Jackson; Kaspar Philipp Holliger; James David Marks; Timothy Piers Clackson; David John Chiswell; Gregory Paul Winter; Timothy Peter Bonnert
- Web page: https://patentgrep.com/patent/US20100136660A1

## CPC

- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/18: against material from animals or humans
- C07K 16/34: against blood group antigens
- C07K 16/40: against enzymes
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 16/462: {Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/73: Expression systems using phage (lambda) regulatory sequences
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/6857: {Antibody fragments}
- B01J 2219/00718: Type of compounds synthesised
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/41: containing a Myc-tag
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS

## Abstract

A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A filamentous bacteriophage particle displaying on its surface a binding molecule which has a binding domain able to bind target epitope or antigen, wherein the binding domain of the binding molecule consists of an antibody heavy chain variable domain with the structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the particle contains nucleic acid with a nucleotide sequence encoding the binding molecule, and the particle is in a population of filamentous bacteriophage particles displaying a population of said binding molecules having a range of binding specificities.

### Claim 8

A population of filamentous bacteriophage particles, the particles displaying on their surface a binding molecule which has a binding domain able to bind target epitope or antigen, wherein the binding domain of the binding molecule consists of an antibody heavy chain variable domain with the structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, the particles contain nucleic acid with a nucleotide sequence encoding the binding molecule, and the population of particles display a population of said binding molecules having a range of binding specificities.

### Claim at position 4

9-17. (canceled)

### Claim 18 (depends on 7)

A filamentous bacteriophage particle according to claim 7 wherein the binding molecule is synthetic.

### Claim 19 (depends on 18)

A filamentous bacteriophage particle according to claim 18 wherein the nucleotide sequence encoding the binding molecule is provided by combining unrearranged V segments with D and J segments.

### Claim 20 (depends on 7)

A filamentous bacteriophage particle according to claim 7 wherein the nucleotide sequence encoding the binding molecule is derived by in vitro mutagenesis of an existing antibody coding sequence or pre-existing phage antibodies.

### Claim 21 (depends on 7)

A filamentous bacteriophage particle according to claim 7 wherein the nucleotide sequence encoding the binding molecule is derived from a peripheral blood lymphocyte.

### Claim 22 (depends on 7)

A filamentous bacteriophage particle according to claim 7 wherein said nucleic acid is comprised in a phagemid genome within the filamentous bacteriophage particle.

### Claim 23 (depends on 8)

A population of filamentous bacteriophage particles according to claim 8 wherein the binding molecules are synthetic.

### Claim 24 (depends on 23)

A population of filamentous bacteriophage particles according to claim 23 wherein the nucleotide sequences encoding the binding molecules are provided by combining unrearranged V segments with D and J segments.

### Claim 25 (depends on 8)

A population of filamentous bacteriophage particles according to claim 8 wherein the nucleotide sequences encoding the binding molecules are derived by in vitro mutagenesis of existing antibody coding sequences or pre-existing phage antibodies.

### Claim 26 (depends on 8)

A population of filamentous bacteriophage particles according to claim 8 wherein the nucleotide sequences encoding the binding molecules are derived from peripheral blood lymphocytes.

### Claim 27 (depends on 8)

A population of filamentous bacteriophage particles according to claim 8 wherein said nucleic acid is comprised in a phagemid genome within the filamentous bacteriophage particles.
